ProtoxTherapeutics Inc. (TSX: PRX), a leader in the development of receptortargeted fusion proteins, today announced that detailed data from itsopen-label Phase 2 clinical study of PRX302 in patients with moderateto severe benign prostatic hyperplasia (BPH) will be presented at the30th World Congress of the Société Internationale d'UrologieConference. The 2009 Congress takes place November 1st - 5th at theShanghai International Convention Center.
Dr. PeterPommerville, M.D., Principal Investigator from the lead site at Can-MedClinical Research Centre (Victoria, B.C.), will present the data. Themoderated poster presentation, entitled "PRX302 is a transperineallyadministered, PSA-activated protoxin that produces symptomatic reliefin men with moderate to severe BPH", will be presented on November 2ndat 3:15pm.
Based on the very promising results from this openlabel Phase 2 study, the Company initiated a double-blinded Phase 2placebo controlled clinical trial called TRIUMPH in the first quarterof 2009. The Company recently announced that enrollment of this studyis complete and anticipate top-line results in the fourth quarter of2009.
Source: PROTOX THERAPEUTICS INC.